Abstract:
In regions where community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is common, oral trimethoprim/sulfamethoxazole(SXT) is a treatment option for skin and soft tissue infections. Recent trials have demonstrated noninferiority of SXT compared to intramuscular benzathine benzylpenicillin or oral clindamycin for treatment of uncomplicated skin and soft tissue infections such as impetigo, cellulitis and simple abscesses. Concern over the increasing rates of community-acquired S. aureus isolates reported as SXT resistant has resulted in recommendations against prescribing SXT for the treatment of skin and soft tissue infections in the Kimberley region of Western Australia.
Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant Staphylococcus aureus clone reveals discrepant resistance reporting
Our findings are crucial in demonstrating that the Northern Territory STS clone is not STX resistant